Abstract:Background: The diagnosis of hepatic sinusoidal obstruction syndrome (HSOS) induced by pyrrolizidine alkaloids is mainly based on clinical investigation. There is currently no prognostic index. This study evaluated the quantitative measurement of blood pyrroleprotein adducts (PPAs) as a diagnostic and prognostic index for pyrrolizidine alkaloid-induced HSOS.Methods: Suspected drug-induced liver injury patients were prospectively recruited. Blood PPAs were quantitatively measured using ultra-performance liquid chromatography-tandem mass spectrometry. Patients' age, sex, biochemistry test results, and a detailed drug history were recorded. The patients were divided into two groups, ie, those with HSOS induced by pyrrolizidine alkaloid-containing drugs and those with liver injury induced by drugs without pyrrolizidine alkaloids. The relationship between herb administration, clinical outcomes, blood sampling time, and blood PPA concentration in pyrrolizidine alkaloid-associated HSOS patients was analyzed using multiple linear regression analysis.Results: Forty patients met the entry criteria, among whom 23 had pyrrolizidine alkaloid-associated HSOS and 17 had liver injury caused by drugs without pyrrolizidine alkaloids. Among the 23 patients with pyrrolizidine alkaloid-associated HSOS, ten recovered, four developed chronic disease, eight died, and one underwent liver transplantation within 6 months after onset. Blood PPAs were detectable in 24 of 40 patients with concentrations from 0.05 to 74.4 nM. Sensitivity and specificity of the test for diagnosis of pyrrolizidine alkaloid-associated HSOS were 100% (23/23) and 94.1% (23/24), respectively. The positive predictive value was 95.8% and the negative predictive value was 100%, whereas the positive likelihood ratio was 23.81. The level of blood PPAs in the severe group (died or received liver transplantation) was significantly higher than that in the recovery/chronicity group (P=0.004).Conclusion: Blood PPAs measured by ultra-performance liquid chromatography-tandem mass spectrometry are highly sensitive and specific for pyrrolizidine alkaloid-associated HSOS. The blood PPA concentration is related to the severity and clinical outcome of pyrrolizidine alkaloid-associated HSOS.

Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome

Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis

Hepatic Sinusoidal Obstruction Syndrome Caused by the Ingestion of Gynura Segetum in a Patient with Alcoholic Cirrhosis: a Case Report.

Prognostic Factors for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome: a Multicenter Study in China

Proteomic Study of Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome in Rats

A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome

Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Gynura japonica Containing Pyrrolizidine Alkaloids

Pyrrolizidine Alkaloids-Induced Hepatic Sinusoidal Obstruction Syndrome: Pathogenesis, Clinical Manifestations, Diagnosis, Treatment, and Outcomes

Blood Pyrrole-Protein Adducts As A Diagnostic and Prognostic Index in Pyrrolizidine Alkaloid-Hepatic Sinusoidal Obstruction Syndrome

Metabolomic and Genomic Evidence for Compromised Bile Acid Homeostasis by Senecionine, A Hepatotoxic Pyrrolizidine Alkaloid

Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by <i>Gynura japonica</i> Containing Pyrrolizidine Alkaloids

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome.

Pyrrolizidine Alkaloids: an Update on Their Metabolism and Hepatotoxicity Mechanism

Prognostic Risk Factors for Patients with Hepatic Sinusoidal Obstruction Syndrome Caused by Pyrrolizidine Alkaloids

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Expert Consensus on the Clinical Management of Pyrrolizidine Alkaloid‐induced Hepatic Sinusoidal Obstruction Syndrome

Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China

First Evidence of Pyrrolizidine Alkaloid N-oxide-induced Hepatic Sinusoidal Obstruction Syndrome in Humans

Farnesoid X receptor contributes to oleanolic acid‐induced cholestatic liver injury in mice

Bear bile powder attenuates senecionine-induced hepatic sinusoidal obstruction syndrome in mice